Michael J. Fox announced he will return for season four of the Apple TV comedy series Shrinking, marking a significant milestone in his acting career that has extended well beyond the initial prognosis he received upon his Parkinson’s diagnosis in 1991. Doctors had predicted he would have approximately 10 years before the neurodegenerative disease would prevent him from performing. Fox, now 65, had previously stepped back from acting during the pandemic due to challenges with his speech but re-entered the industry after reconnecting with Bill Lawrence, the show’s creator and a collaborator from Fox’s Spin City days.
Fox stated that returning to acting has substantially improved his quality of life, describing it as having “really prolonged my life and made my life interesting.” On Shrinking, Fox appears opposite Harrison Ford in a storyline where both characters contend with Parkinson’s. Fox noted that Ford’s portrayal of a character with the condition was authentic and that the two actors developed a meaningful on-screen relationship.
Beyond his acting pursuits, Fox has maintained a significant presence in Parkinson’s research and advocacy through the Michael J. Fox Foundation, which he established in 2000 with business partner Deborah W. Brooks. The foundation has funded more than $3 billion in research and has become one of the most successful disease-focused nonprofits of the century. Brooks noted that when the organization began, virtually no Parkinson’s treatments were in human testing; today approximately 180 active drug programs are undergoing human trials.
Fox initially kept his diagnosis private for seven years while starring in Spin City. After going public, he became the visible face of a community that had previously remained largely hidden from public view. His advocacy has included testifying before the Senate without medication to demonstrate the disease’s effects, and he has participated in various media appearances to normalize the condition.
The foundation is targeting $700 million in new research commitments this year, nearly triple the amount the U.S. government funded for Parkinson’s research in 2025. Fox and Brooks both expressed optimism about recent scientific advances, including stem cell research innovations and biomarker testing that allows for early diagnosis before symptom onset.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI